Trump’s Medicaid cuts strip refugees and other legal immigrants of their health coverage - The Spec

Dalhousie University researcher Dr. Raluca Bejan’s research complicates the story of who Europe deems a “deserving” refugee When Russia invaded Ukraine in 2022, the world watched as neighbouring European countries opened their borders to Ukrainian refugees — a welcome that stood in sharp contrast to the reception often given to refugees fleeing Africa and the Middle East. Many observers pointed to race as the reason. A new book from Dalhousie University's Dr. Raluca Bejan argues the real story is far more complex.

Bioengineer.org news storyFor millions of people living with HIV, antiretroviral therapy has transformed a once-fatal infection into a manageable chronic condition. Yet the very drugs that suppress the virus can carry quiet costs, and one of the most insidious is bone loss. Tenofovir disoproxil fumarate, or TDF, has been a cornerstone of HIV treatment worldwide for two decades, prized for its potency, durability, and low cost. But a growing body of evidence has linked TDF exposure to measurable reductions in bone mineral density, raising an increasingly urgent clinical question: once bone has been lost on a TDF-based regimen, can it be recovered? A new prospective cohort study, published in BMC Infectious Diseases, offers some of the most detailed longitudinal evidence to date that the answer, for many patients, is yes. The research team enrolled 223 virologically suppressed men living with HIV who had low bone mineral density while taking TDF-based antiretroviral therapy.